Literature DB >> 36162983

Correction: Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients.

Bihua Wang1,2, Zhidan Zhu1,2, Feng Huang1,2, Haowen Huang3, Luxia Tu4, Ying Wang1, Linfeng Zheng1, Jing Zhou1, Xin Wei5.   

Abstract

Entities:  

Year:  2022        PMID： 36162983      PMCID： PMC9513965          DOI： 10.1186/s12882-022-02950-0

Source DB:  PubMed          Journal:  BMC Nephrol        ISSN： 1471-2369            Impact factor:   2.585


× No keyword cloud information.
Correction: BMC Nephrol 23, 306 (2022) https://doi.org/10.1186/s12882-022-02914-4 Following publication of the original article [1], the authors informed us that the first “Excluded” box in Fig. 1 is incomplete. The correct Fig. 1 is given below.
Fig. 1

Inclusion flowchart of patients with idiopathic membranous nephropathy

Inclusion flowchart of patients with idiopathic membranous nephropathy The original article has been corrected.
  1 in total

1.  Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients.

Authors:  Bihua Wang; Zhidan Zhu; Feng Huang; Haowen Huang; Luxia Tu; Ying Wang; Linfeng Zheng; Jing Zhou; Xin Wei
Journal:  BMC Nephrol       Date:  2022-09-07       Impact factor: 2.585
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.